Matching articles for "Lipidil"
Lipid-Lowering Drugs
The Medical Letter on Drugs and Therapeutics • September 19, 2022; (Issue 1659)
Cholesterol management guidelines from the
American College of Cardiology/American Heart
Association Task Force were last published in...
Cholesterol management guidelines from the
American College of Cardiology/American Heart
Association Task Force were last published in 2019.
Comparison Table: Some Lipid-Lowering Drugs (online only)
The Medical Letter on Drugs and Therapeutics • September 19, 2022; (Issue 1659)
...
View the Comparison Table: Some Lipid-Lowering Drugs
Lipid-Lowering Drugs
The Medical Letter on Drugs and Therapeutics • February 11, 2019; (Issue 1565)
Cholesterol management guidelines from the American
College of Cardiology/American Heart Association Task
Force have recently been published. See Table 1 for a
brief summary of their...
Cholesterol management guidelines from the American
College of Cardiology/American Heart Association Task
Force have recently been published. See Table 1 for a
brief summary of their recommendations.
Lipid-Lowering Drugs
The Medical Letter on Drugs and Therapeutics • October 24, 2016; (Issue 1506)
Lipid-lowering drugs should be taken indefinitely;
when they are stopped, plasma lipoproteins return to
pretreatment levels. HMG-CoA reductase inhibitors
(statins) remain the drugs of choice for treatment...
Lipid-lowering drugs should be taken indefinitely;
when they are stopped, plasma lipoproteins return to
pretreatment levels. HMG-CoA reductase inhibitors
(statins) remain the drugs of choice for treatment of
most patients who require lipid-lowering therapy.
Fenofibric Acid (Trilipix)
The Medical Letter on Drugs and Therapeutics • May 4, 2009; (Issue 1311)
The FDA has approved the marketing of fenofibric acid (Trilipix - Abbott) to reduce triglycerides and increase HDL-C in patients with mixed dyslipidemia on optimal doses of a HMG-CoA reductase inhibitor...
The FDA has approved the marketing of fenofibric acid (Trilipix - Abbott) to reduce triglycerides and increase HDL-C in patients with mixed dyslipidemia on optimal doses of a HMG-CoA reductase inhibitor (statin) who have, or have risk factors for, coronary heart disease. It is the first fibrate approved by the FDA specifically for combined use with a statin. Trilipix is also approved as monotherapy for hypertriglyceridemia, hypercholesterolemia and low HDL-C. The patent for Tricor, Abbott's older formulation of fenofibrate, will expire in 2011.
Simcor: A Niacin/Simvastatin Combination
The Medical Letter on Drugs and Therapeutics • April 7, 2008; (Issue 1283)
The FDA has approved the marketing of a second fixed-dose combination of extended-release niacin (Niaspan) with a generic statin. Niaspan/simvastatin (Simcor - Abbott) is approved for use in patients with...
The FDA has approved the marketing of a second fixed-dose combination of extended-release niacin (Niaspan) with a generic statin. Niaspan/simvastatin (Simcor - Abbott) is approved for use in patients with hypercholesterolemia or mixed dyslipidemia (high LDL-cholesterol, low HDL-cholesterol and high serum triglycerides). Niaspan/lovastatin (Advicor) was marketed previously for the same indications.
Omega-3 Polyunsaturated Fatty Acids (Omacor) for Hypertriglyceridemia
The Medical Letter on Drugs and Therapeutics • November 7, 2005; (Issue 1221)
A highly concentrated omega-3 polyunsaturated fatty acid (PUFA) preparation (Omacor - Reliant) has been approved by the FDA as an adjunct to diet for treatment of very high plasma triglyceride concentrations...
A highly concentrated omega-3 polyunsaturated fatty acid (PUFA) preparation (Omacor - Reliant) has been approved by the FDA as an adjunct to diet for treatment of very high plasma triglyceride concentrations (>=500 mg/dL). Omacor is a combination of the ethyl esters of icosapentaenoic (EPA) and docosahexaenoic (DHA) acids. It is the first drug derived from omega-3 PUFAs to be sold by prescription.
Lp-PLA2: a New Marker of Vascular Risk
The Medical Letter on Drugs and Therapeutics • October 13, 2003; (Issue 1167)
Lipoprotein associated phospholipase A2 (Lp-PLA2), an enzyme involved in the repair of oxidative damage to lipoproteins, causes release of inflammatory mediators associated with atherosclerosis. A new assay,...
Lipoprotein associated phospholipase A2 (Lp-PLA2), an enzyme involved in the repair of oxidative damage to lipoproteins, causes release of inflammatory mediators associated with atherosclerosis. A new assay, PLAC (diaDexus, Inc.), is now available to measure Lp-PLA2 levels. C-reactive protein (CRP), another inflammatory mediator, appears to be a biomarker for coronary disease (MH Shishehbor et al, Cleve Clin J Med 2003; 70:634). The role of Lp-PLA2 testing in determining cardiovascular risk is less clear.